Xiangyu Medical Reports Nearly 91% Surge in Net Profit in 2023 Performance Forecast

Jan 30, 2024 00:06 CST Updated 00:07

Sunnyou

Intelligent Rehabilitation Equipment R&D and Manufacturer

Source of the article: Siyu MedTech; Editor: Zheng Siyu

Reprint Requirements: Please indicate the source of the article at the beginning of the text, and it can be reprinted directly.

January 24, 2024Sunnyou Medical (688626)DisclosureThe 2023 Annual Performance Forecast.

The company expects to achieve operating revenue of 730-750 million yuan in the fiscal year 2023, representing an increase of 241-261 million yuan compared to the same period last year (legally disclosed data), with a year-on-year growth of 49.43% to 53.52%.

ExpectedThe net profit attributable to the parent company for the fiscal year 2023 is expected to reach 220-240 million yuan, representing an increase of 95-115 million yuan compared to the same period last year (as per statutory disclosure data).An increase of 75.34% to 91.28% year-on-year；

It is expected that the net profit attributable to the parent company's owners, excluding non-recurring gains and losses, will be 190-210 million yuan for the fiscal year 2023.RMB, compared with the same period last year (statutory disclosure data), will increase by 112-132 million yuan, representing a year-on-year growth of 144.26% to 169.97%.

The reason for this change in performance was explained in the announcement as:

The company has always attached importance to the research and development of new products, continuously enriched its rehabilitation product line, while strengthening the layout of its marketing network and the construction of its marketing system. With the elimination of factors affecting economic development and the growth in demand for rehabilitation medical services, the company achieved an increase in sales orders during the reporting period, which in turn drove a rapid growth in net profit.

Sunnyou Medical's Q3 2023 Report Shows: Main Business Revenue of 542 Million Yuan, Up 51.99% Year-on-Year; Net Profit Attributable to Shareholders of 179 Million Yuan, Up 92.83% Year-on-Year; Non-recurring Net Profit of 165 Million Yuan, Up 194.97% Year-on-Year; In Q3 2023 Alone, the Company’s Quarterly Main Business Revenue Reached 207 Million Yuan, Up 52.7% Year-on-Year; Quarterly Net Profit Attributable to Shareholders Was 71.5494 Million Yuan, Up 35.24% Year-on-Year; Quarterly Non-recurring Net Profit Was 69.9411 Million Yuan, Up 131.7% Year-on-Year.

#About Sunnyou

Sunnyou (XIANGYU MEDICAL) was founded in 2002, asA Leading R&D Enterprise in China's Rehabilitation Medical Device IndustrySunnyou, which was listed on the STAR Market in March 2021, mainly provides a full range of rehabilitation products and comprehensive solutions to various levels of medical institutions across China, including general hospitals, rehabilitation hospitals, grassroots clinics, elderly care facilities, disabled rehabilitation centers, and welfare organizations.

The company always regards technological innovation as the primary driving force for development, and is committed toIntelligent rehabilitation equipment in fields such as orthopedic rehabilitation, neurological rehabilitation, critical care rehabilitation, pain rehabilitation, postpartum rehabilitation, and integrated medical-care.independently research, produce, promote, and sell, assisting in building a smart health care service guarantee system covering all populations, all diseases, and the entire life process.

Editor-in-Chief | Zhao Qing Reviewed by | Yi He